SCHEMBL6214319

SCHEMBL6214319

NCc1cc(Cl)ccc1OCc1ccns1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR5 P51681 1/20 0.47
▸ MRGPRX4 Q96LA9 3/20 0.39
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ SENP8 Q96LD8 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ SENP6 Q9GZR1 1/20 0.36
▸ PTGER1 P34995 8/20 0.35
▸ STAT3 P40763 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6212832 0.76 GRM5 (0.47) PTGER1
SCHEMBL6210923 0.76 CCR5 (0.48) CCR5MRGPRX4NPC1SMN1; SMN2LMNA
SCHEMBL6212464 0.75 CCR5 (0.47) CCR5MRGPRX4SMN1; SMN2LMNAPTGER1
Hydrochloric Acid SCHEMBL6215773 0.73 CCR5 (0.75) CCR5MRGPRX4PTGER1STAT3
SCHEMBL6213919 0.72 CCR5 (0.44) CCR5MRGPRX4NPC1RAB9ALMNA
SCHEMBL1196687 0.72 CCR5 (0.64) CCR5MRGPRX4PTGER1STAT3
SCHEMBL6214597 0.71 SLC6A4 (0.57) CCR5MRGPRX4PTGER1
SCHEMBL14785504 0.71 PTGER1 (0.54) CCR5SMN1; SMN2LMNAPTGER1MAPT
Hydrochloric Acid SCHEMBL6214742 0.71 CCR5 (0.62) CCR5MRGPRX4PTGER1STAT3
Hydrochloric Acid SCHEMBL6213801 0.70 MEN1 (0.50) CCR5MRGPRX4NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216257-B1 COMPOUNDS FOR THE TREATMENT OF ISCHEMIA PFIZER PROD INC (US) 2005-12-07 — — EP disclosed
US-6803457-B1 ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS PFIZER, INC. 2004-10-12 — — US disclosed
US-20040198693-A1 Compounds for the treatment of ischemia DENINNO MICHAEL P (US) 2004-10-07 — — US disclosed
EP-1216257-A1 COMPOUNDS FOR THE TREATMENT OF ISCHEMIA Pfizer Products Inc. (US) 2002-06-26 — — EP disclosed
WO-2001023399-A1 COMPOUNDS FOR THE TREATMENT OF ISCHEMIA PFIZER PRODUCTS INC. (US) 2001-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198693-A1 Compounds for the treatment of ischemia TNNI3, ADRB3, FABP3 CCR5 2406/4885MRGPRX4 362/4885NPC1 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback